미국의 제산제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 최종 용도별, 주요 기업별, 경쟁 분석, 부문별 예측(2025-2030년)

U.S. Antacids Market Summary

The U.S. antacids market size was estimated at USD 3.00 billion in 2024 and is projected to reach USD 3.73 billion in 2030, growing at a CAGR of 3.7% from 2025 to 2030. Changing dietary habits is a key factor propelling market growth over the forecast period.

Rising cases of digestive issues such as gastroesophageal reflux disease (GERD), peptic ulcers, and other stomach problems that cause acidity, indigestion, and heartburn are also expected to support market expansion. According to a report published by the CDC in December 2024, approximately 5.9% U.S. adults were diagnosed with ulcers. Other key drivers include rising awareness and easy access to over-the-counter (OTC) antacids, which provide fast and effective relief from symptoms.

In addition, lifestyle factors such as stress, smoking, alcohol use, poor diet, and obesity, all of which contribute to acid-related conditions, are expected to further influence the growth of the U.S. antacid industry. For instance, according to a report by the CDC published in September 2024, the prevalence of obesity was 40.3% among adults in the U.S. from August 2021 to August 2023. The highest rates are seen in adults aged 40-59 and those with lower education levels. Severe obesity affected 9.4% of adults, with women showing higher rates than men across all age groups.

Most product development focuses on delivery formats such as chewable, liquids, fast-dissolve tablets, and branding. Some moderate innovation comes from combo formulations or OTC-probiotic hybrids which are expected to drive the demand for U.S. antacid industry.

The U.S. antacid market is subject to the high impact of regulations, particularly because antacids are available over-the-counter (OTC). The FDA monitors formulation, labeling, and marketing claims to ensure safety and efficacy. New formulations or combinations must meet specific OTC monograph standards, and some ingredients, such as ranitidine, have been withdrawn due to safety concerns. This means manufacturers must continuously adapt to evolving regulatory guidelines, especially around product safety, recalls, and transparency.

U.S. Antacids Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the U.S. antacid market on the basis of types, and end-use:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Tablet
• Liquid
• Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospital Pharmacy
• Retail Pharmacy
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. End use
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. End use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Antacid Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Antacid Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. U.S. Antacid Market: Pipeline Analysis

Chapter 4. U.S. Antacid Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. U.S. Antacid Market: Type Movement Analysis
• 4.3. U.S. Antacid Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Tablet
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Liquid
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Antacid Market: End use Estimates & Trend Analysis

• 5.1. End use Segment Dashboard
• 5.2. U.S. Antacid Market: End use Movement Analysis
• 5.3. U.S. Antacid Market Size & Trend Analysis, by End use, 2018 to 2030 (USD Million)
• 5.4. Hospital Pharmacy
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Retail Pharmacy
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. Key company heat map analysis, 2024
• 6.4. Company Profiles
  • 6.4.1. Haleon Group of Companies.
    • 6.4.1.1. Company overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Type benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. Bayer AG
    • 6.4.2.1. Company overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Type benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Boehringer Ingelheim International GmbH
    • 6.4.3.1. Company overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Type benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Dr. Reddy's Laboratories Ltd.
    • 6.4.4.1. Company overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Type benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Sanofi
    • 6.4.5.1. Company overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Type benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. Reckitt Benckiser Group plc
    • 6.4.6.1. Company overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Type benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Sun Pharmaceuticals Ltd.
    • 6.4.7.1. Company overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Type benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. Takeda Pharmaceutical Company Limited
    • 6.4.8.1. Company overview
    • 6.4.8.2. Financial performance
    • 6.4.8.3. Type benchmarking
    • 6.4.8.4. Strategic initiatives
  • 6.4.9. Pfizer Inc.
    • 6.4.9.1. Company overview
    • 6.4.9.2. Financial performance
    • 6.4.9.3. Type benchmarking
    • 6.4.9.4. Strategic initiatives
  • 6.4.10. Procter & Gamble
    • 6.4.10.1. Company overview
    • 6.4.10.2. Financial performance
    • 6.4.10.3. Type benchmarking
    • 6.4.10.4. Strategic initiatives